Business
Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
Interim biomarker-rich Phase 1 data for JADE101 to be featured in an oral session at the 63rd European Renal Association Congress Phase 2 trial of JADE101 in IgA nephropathy patients expected to begin in the second quarter of 2026; interim data expected in 2027 Phase 1 study of JADE201, a half-life extended afucosylated anti-BAFF-R antibody, expected to begin in the second quarter of 2026; interim data expected in 2027 Phase 1 clinical trial for JADE301 remains on track to begin in the first hal
About this update from Jade Biosciences, Inc.
[{"type":"image","alt":"Jade Biosciences","displaySize":"","headline":null,"caption":"Jade Biosciences","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":112,"url":"https://media.zenfs.com/en/globenewswire.com/345f7337e814bf11ed72261f2fc78278"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/DtRhwV3KjbfNt1TBBxBOZw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1Nw--/https://media.zenfs.com/en/globenewswire.com/345f7337e814bf11ed72261f2fc78278","width":300,"height":112},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/DtRhwV3KjbfNt1TBBxBOZw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1Nw--/https://media.zenfs.com/en/globenewswire.com/345f7337e814bf11ed72261f2fc78278","width":300,"height":112}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Interim biomarker-rich Phase 1 data for JADE101 to be featured in an oral session at the 63rd European Renal Association Congress ","length":129,"tagName":"p"}]},{"val":[{"type":"text","content":"Phase 2 trial of JADE101 in IgA nephropathy patients expected to begin in the second quarter of 2026; interim data expected in 2027 ","length":131,"tagName":"p"}]},{"val":[{"type":"text","content":"Phase 1 study of JADE201, a half-life extended afucosylated anti-BAFF-R antibody, expected to begin in the second quarter of 2026; interim data expected in 2027 ","length":160,"tagName":"p"}]},{"val":[{"type":"text","content":"Phase 1 clinical trial for JADE301 remains on track to begin in the first half of 2027 ","length":86,"tagName":"p"}]},{"val":[{"type":"text","content":"$311 million in cash, cash equivalents, and investments as of March 31, 2026 expected to provide runway into the first half of 2028","length":131,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":637,"olType":false},{"type":"text","content":"SAN FRANCISCO and VANCOUVER, British Columbia, May 07, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced financial results for the first quarter ending March 31, 2026, and provided a corporate update.","length":351,"tagName":"p"},{"type":"text","content":"“With the upcoming initial biomarker-rich Phase 1 data for our lead program, JADE101, and an additional program expected to enter the clinic this quarter, we ...